Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

(2023) Jing Zou et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis

(2023) Yang Pan et al.   LANCET

Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination

(2022) Samuel M. S. Cheng et al.   NATURE MEDICINE

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

(2022) Jingxin Li et al.   NATURE MEDICINE

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons

(2022) Annika Rössler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine

(2022) Sitthichai Kanokudom et al.   Vaccines

Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants

(2022) Ruiqi Zhang et al.   Vaccines

Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant

(2022) Ka-Wa Khong et al.   Vaccines

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

(2022) Gili Regev-Yochay et al.   NEW ENGLAND JOURNAL OF MEDICINE

mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern

(2022) Haomeng Wang et al.   Emerging Microbes & Infections

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people

(2022) Santiago Oviedo Rouco et al.   LANCET INFECTIOUS DISEASES

Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates

(2021) Qian He et al.   Emerging Microbes & Infections

A global database of COVID-19 vaccinations

(2021) Edouard Mathieu et al.   Nature Human Behaviour

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

(2021) Jackson S. Turner et al.   NATURE

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

(2021) Angela Choi et al.   NATURE MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

(2021) Stephen J. Thomas et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

(2021) Markus Hoffmann et al.   CELL

Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021

(2021) Margaux MI Meslé et al.   Eurosurveillance

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

(2021) Rishi R. Goel et al.   SCIENCE

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

(2020) Evan J. Anderson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

(2019) Robert A. Feldman et al.   VACCINE

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

(2017) Martin Alberer et al.   LANCET